Amalgamated Financial’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Amalgamated Financial’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$988K	Buy	+8,329	New	+$1.04M	0.01%	1177

Other funds holding BHVN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Amalgamated Financial's BHVN Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q1 2022: 8,329 shares worth $988K. The stake represents 0.01% of the portfolio and ranks #1177 among its holdings.

307 funds tracked by Wall St. Rank hold BHVN as of Q1 2022.

Amalgamated Financial held 8,329 shares of Biohaven Pharmaceutical Holding Company Ltd. worth $988K as of Q1 2022.
Biohaven Pharmaceutical Holding Company Ltd. was a new Amalgamated Financial position in Q1 2022.
Biohaven Pharmaceutical Holding Company Ltd. made up 0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1177 holding.
307 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.